PLUS THERAPEUTICS Files 8-K on Shareholder Nominations
Ticker: PSTV · Form: 8-K · Filed: May 20, 2024 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | May 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-action, filing
TL;DR
PLUS THERAPEUTICS filed an 8-K about shareholder nominations for the annual meeting. Board changes could be coming.
AI Summary
On May 16, 2024, PLUS THERAPEUTICS, INC. filed an 8-K report detailing shareholder nominations for its upcoming annual meeting. The company, formerly known as CYTORI THERAPEUTICS, INC. and MACROPORE INC, is based in Austin, Texas, and operates in the surgical and medical instruments sector.
Why It Matters
This filing indicates potential changes or challenges to the current board composition, which could impact the company's strategic direction and future performance.
Risk Assessment
Risk Level: medium — Shareholder nominations can signal activism or dissatisfaction, potentially leading to changes in leadership or strategy.
Key Numbers
- 001-34375 — SEC File Number (Identifies the company's filing history with the SEC.)
- 33-0827593 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- CYTORI THERAPEUTICS, INC. (company) — Former company name
- MACROPORE INC (company) — Former company name
- May 16, 2024 (date) — Date of earliest event reported
- Austin, Texas (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to report shareholder nominations for the company's upcoming annual meeting, as well as other events.
When was the earliest event reported in this filing?
The earliest event reported was on May 16, 2024.
What are the former names of PLUS THERAPEUTICS, INC.?
The former names were CYTORI THERAPEUTICS, INC. and MACROPORE INC.
Where are the principal executive offices of PLUS THERAPEUTICS, INC. located?
The principal executive offices are located at 4200 Marathon Blvd., Suite 200, Austin, Texas 78756.
What is the Standard Industrial Classification (SIC) code for PLUS THERAPEUTICS, INC.?
The SIC code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-05-20 07:00:11
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PSTV The Nasdaq
Filing Documents
- pstv-20240516.htm (8-K) — 44KB
- 0000950170-24-062116.txt ( ) — 162KB
- pstv-20240516.xsd (EX-101.SCH) — 30KB
- pstv-20240516_htm.xml (XML) — 5KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations. To the extent applicable, the information in Item 8.01 of this report is incorporated by reference into this Item 5.08.
01 Other Events
Item 8.01 Other Events. On May 16, 2024, the Board of Directors of Plus Therapeutics, Inc. (the "Company") determined that the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting") will be held on Thursday, August 15, 2024, at 9:00 a.m. Eastern Time. The Annual Meeting will be held virtually by means of remote communication. Stockholders of record of the Company's common stock at the close of business on June 25, 2024 will be entitled to notice of, and to vote at, the Annual Meeting. The Company, however, reserves the right to change the record date, and the date, time and place of the Annual Meeting prior to the Annual Meeting. Pursuant to the Company's Bylaws (the "Bylaws"), stockholders seeking to bring business before the Annual Meeting or to nominate candidates for election as directors at the Annual Meeting must deliver such proposals or nominations to 4200 Marathon Blvd., Suite 200, Austin, Texas 78756, Attention: Corporate Secretary, not later than 5:00 p.m. Eastern Time on Thursday, May 30, 2024. Any stockholder proposal or director nomination must also comply with the requirements of Delaware law, the rules and regulations promulgated by the SEC and the Bylaws, as applicable.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLUS THERAPEUTICS, INC. Date: May 20, 2024 By: /s/ Andrew Sims Name: Andrew Sims Title: Chief Financial Officer